{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T21:37:43Z","timestamp":1768081063433,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CHE-9974839"],"award-info":[{"award-number":["CHE-9974839"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s11095-019-2600-0","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T16:28:38Z","timestamp":1554913718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Oligo(Lactic Acid)8-Rapamycin Prodrug-Loaded Poly(Ethylene Glycol)-block-Poly(Lactic Acid) Micelles for Injection"],"prefix":"10.1007","volume":"36","author":[{"given":"Yu Tong","family":"Tam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Repp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Xiong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Feltenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-1361","authenticated-orcid":false,"given":"Glen S.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"issue":"1","key":"2600_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrm3025","volume":"12","author":"R Zoncu","year":"2011","unstructured":"Zoncu R, Efeyan A, Sabatini DM. MTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21\u201335.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2600_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","volume":"7","author":"J Dancey","year":"2010","unstructured":"Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010;7:209\u201310.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2600_CR3","first-page":"15","volume":"7","author":"Y Zheng","year":"2015","unstructured":"Zheng Y, Jiang Y. mTOR inhibitors at a glance. Mol Cell Pharmacol. 2015;7(2):15\u201320.","journal-title":"Mol Cell Pharmacol"},{"issue":"3","key":"2600_CR4","first-page":"1","volume":"8","author":"T Lin","year":"2016","unstructured":"Lin T, Leung C, Nguyen K, Figlin RA. Mammalian target of rapamycin (mTOR) inhibitors in solid tumours. Cinical Pharm. 2016;8(3):1\u201323.","journal-title":"Cinical Pharm"},{"issue":"2","key":"2600_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jconrel.2005.10.008","volume":"110","author":"ML Forrest","year":"2006","unstructured":"Forrest ML, Won CY, Malick AW, Kwon GS. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(\u03b5-caprolactone) micelles. J Control Release. 2006;110(2):370\u20137.","journal-title":"J Control Release"},{"key":"2600_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/00007691-199512000-00020","volume":"17","author":"RW Yatscoff","year":"1995","unstructured":"Yatscoff RW, Wang P, Chan K, Hicks D, Zimmerman J. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit. 1995;17:666\u201371.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"2600_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.clpt.6100317","volume":"82","author":"CM Hartford","year":"2007","unstructured":"Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007;82(4):381\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2600_CR8","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/1078-0432.CCR-07-4719","volume":"14","author":"BI Rini","year":"2008","unstructured":"Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res. 2008;14(5):1286\u201390.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2600_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.clgc.2014.07.006","volume":"13","author":"R Iacovelli","year":"2015","unstructured":"Iacovelli R, Santoni M, Verzoni E, Grassi P, Testa I, De Braud F, et al. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. Clin Genitourin Cancer. 2015;13(2):137\u201341.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"2600_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","volume":"6","author":"SA Soefje","year":"2011","unstructured":"Soefje SA, Karnad A, Brenner AJ. Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol. 2011;6(2):125\u20139.","journal-title":"Target Oncol"},{"issue":"12","key":"2600_CR11","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","volume":"22","author":"E Raymond","year":"2004","unstructured":"Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22(12):2336\u201347.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2600_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00280-007-0458-z","volume":"61","author":"JA Y\u00e1\u00f1ez","year":"2008","unstructured":"Y\u00e1\u00f1ez JA, Forrest ML, Ohgami Y, Kwon GS, Davies NM. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(\u03b5- caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol. 2008;61(1):133\u201344.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2600_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/340315","volume":"2013","author":"W Xu","year":"2013","unstructured":"Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv. 2013;2013:1\u201315.","journal-title":"J Drug Deliv"},{"issue":"8","key":"2600_CR14","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1021\/acs.molpharmaceut.7b00188","volume":"14","author":"L Houdaihed","year":"2017","unstructured":"Houdaihed L, Evans JC, Allen C. Overcoming the road blocks: advancement of block copolymer micelles for cancer therapy in the clinic. Mol Pharm. 2017;14(8):2503\u201317.","journal-title":"Mol Pharm"},{"issue":"3","key":"2600_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11705-016-1582-2","volume":"10","author":"DH Shin","year":"2016","unstructured":"Shin DH, Tam YT, Kwon GS. Polymeric micelle nanocarriers in cancer research. Front Chem Sci Eng. 2016;10(3):348\u201359.","journal-title":"Front Chem Sci Eng"},{"key":"2600_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jconrel.2015.12.015","volume":"240","author":"H Cho","year":"2016","unstructured":"Cho H, Gao J, Kwon GS. PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol\u2013gels for drug delivery. J Control Release. 2016;240:191\u2013201.","journal-title":"J Control Release"},{"issue":"7059","key":"2600_CR17","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/nature04162","volume":"437","author":"D Chandler","year":"2005","unstructured":"Chandler D. Interfaces and the driving force of hydrophobic assembly. Nature. 2005;437(7059):640\u20137.","journal-title":"Nature."},{"issue":"11","key":"2600_CR18","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1021\/la001226i","volume":"17","author":"T Riley","year":"2001","unstructured":"Riley T, Stolnik S, Heald CR, Xiong CD, Garnett MC, Illum L, et al. Physicochemical evaluation of nanoparticles assembled from poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) block copolymers as drug delivery vehicles. Langmuir. 2001;17(11):3168\u201374.","journal-title":"Langmuir."},{"issue":"1","key":"2600_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nantod.2012.01.002","volume":"7","author":"SC Owen","year":"2012","unstructured":"Owen SC, Chan DPY, Shoichet MS. Polymeric micelle stability. Nano Today. 2012;7(1):53\u201365.","journal-title":"Nano Today"},{"issue":"14","key":"2600_CR20","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1021\/acs.chemrev.8b00199","volume":"118","author":"H Cabral","year":"2018","unstructured":"Cabral H, Miyata K, Osada K, Kataoka K. Block copolymer micelles in nanomedicine applications. Chem Rev. 2018;118(14):6844\u201392.","journal-title":"Chem Rev"},{"issue":"28","key":"2600_CR21","doi-asserted-by":"publisher","first-page":"8674","DOI":"10.1021\/jacs.6b03995","volume":"138","author":"YT Tam","year":"2016","unstructured":"Tam YT, Gao J, Kwon GS. Oligo(lactic acid)n-paclitaxel prodrugs for poly(ethylene glycol)-block-poly(lactic acid) micelles: loading, release, and backbiting conversion for anticancer activity. J Am Chem Soc. 2016;138(28):8674\u20137.","journal-title":"J Am Chem Soc"},{"issue":"7","key":"2600_CR22","doi-asserted-by":"publisher","first-page":"7406","DOI":"10.1021\/acsnano.8b04205","volume":"12","author":"YT Tam","year":"2018","unstructured":"Tam YT, Huang C, Poellmann M, Kwon GS. Stereocomplex prodrugs of oligo(lactic acid)n-gemcitabine in poly(ethylene glycol)- block-poly(d, l -lactic acid) micelles for improved physical stability and enhanced antitumor efficacy. ACS Nano. 2018;12(7):7406\u201314.","journal-title":"ACS Nano"},{"issue":"19","key":"2600_CR23","doi-asserted-by":"publisher","first-page":"6397","DOI":"10.1021\/ma980553i","volume":"31","author":"SJ De Jong","year":"1998","unstructured":"De Jong SJ, Van Dijk-Wolthuis WNE, Kettenes-Van Den Bosch JJ, PJW S, Hennink WE. Monodisperse enantiomeric lactic acid oligomers: preparation, characterization, and stereocomplex formation. Macromolecules. 1998;31(19):6397\u2013402.","journal-title":"Macromolecules."},{"key":"2600_CR24","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1002\/pola.22944","volume":"46","author":"K Takizawa","year":"2008","unstructured":"Takizawa K, Nulwala H, Hu J, Yoshinaga K, Hawker CJ. Molecularly defined (L)-lactic acid oligomers and polymers: synthesis and characterization. J Poly Sci. 2008;46:5977\u201390.","journal-title":"J Poly Sci"},{"issue":"11","key":"2600_CR25","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/nprot.2007.391","volume":"2","author":"S Kaihara","year":"2007","unstructured":"Kaihara S, Matsumura S, Mikos AG, Fisher JP. Synthesis of poly(L-lactide) and polyglycolide by ring-opening polymerization. Nat Protoc. 2007;2(11):2667\u201371.","journal-title":"Nat Protoc"},{"issue":"20","key":"2600_CR26","doi-asserted-by":"publisher","first-page":"6779","DOI":"10.1016\/j.polymer.2004.08.001","volume":"45","author":"CF Van Nostrum","year":"2004","unstructured":"Van Nostrum CF, Veldhuis TFJ, Bos GW, Hennink WE. Hydrolytic degradation of oligo(lactic acid): a kinetic and mechanistic study. Polymer. 2004;45(20):6779\u201387.","journal-title":"Polymer."},{"issue":"5","key":"2600_CR27","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.bmcl.2017.01.069","volume":"27","author":"H Wang","year":"2017","unstructured":"Wang H, Zheng X, Cai Z, Yu O, Zheng S, Zhu T. Synthesis and evaluation of an injectable everolimus prodrug. Bioorganic Med Chem Lett. 2017;27(5):1175\u20138.","journal-title":"Bioorganic Med Chem Lett"},{"issue":"3","key":"2600_CR28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s11095-013-1192-3","volume":"31","author":"W Tai","year":"2014","unstructured":"Tai W, Chen Z, Barve A, Peng Z, Cheng K. A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer. Pharm Res. 2014;31(3):706\u201319.","journal-title":"Pharm Res"},{"key":"2600_CR29","first-page":"2197","volume":"7","author":"HN Woo","year":"2012","unstructured":"Woo HN, Chung HK, Ju EJ, Jung J, Kang H-W, Lee S-W, et al. Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy. Int J Nanomedicine. 2012;7:2197\u2013208.","journal-title":"Int J Nanomedicine"},{"issue":"10","key":"2600_CR30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/aps.2015.68","volume":"36","author":"LH Meng","year":"2015","unstructured":"Meng LH, Zheng XS. Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol Sin. 2015;36(10):1163\u20139.","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"2600_CR31","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/jps.20542","volume":"95","author":"BM Liederer","year":"2006","unstructured":"Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci. 2006;95(6):1177\u201395.","journal-title":"J Pharm Sci"},{"key":"2600_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jconrel.2019.02.017","volume":"298","author":"YT Tam","year":"2019","unstructured":"Tam YT, Shin DH, Chen KE, Kwon GS. Poly(ethylene glycol)-block-poly(D,L-lactic acid) micelles containing oligo (lactic acid)8-paclitaxel prodrug: in vivo conversion and antitumor efficacy. J Control Release. 2019;298:186\u201393.","journal-title":"J Control Release"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-019-2600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-019-2600-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-019-2600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T08:27:05Z","timestamp":1589704025000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-019-2600-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["2600"],"URL":"https:\/\/doi.org\/10.1007\/s11095-019-2600-0","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]},"assertion":[{"value":"26 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"70"}}